The Department of Biotechnology (DBT), under its advanced technology scheme, Biotechnology Industry Partnership Programme (BIPP), has invited fresh proposals from biotech companies for providing support on a cost sharing basis targeted at development of novel and high risk futuristic technologies mainly for viability gap funding and enhancing existing R&D capacities of start-ups and SMEs in key areas of national importance and public good.
DBT is operating this scheme through Biotechnology Industry Research Assistance Programme (BIRAP), a not-for-profit public sector undertaking set up by DBT to promote and nurture innovation research in biotech enterprises specially start-ups and SMEs. Major thrust of the programme is towards funding technologies which address a major national problem and/or involves high level of innovation. The proposals spanning across the spectrum of pre-proof-of-concept to validation of established technologies are considered for support in the form of grant and loan.
The scheme supports large, medium, small scale companies as well as start-up on cost sharing basis. It would push for high risk, discovery linked innovation and accelerated technology development. Varying models of grants, loans or grant plus loans will be made available under the scheme. It will be one of the most enabling mechanisms to promote R&D in biotech industry and public private partnership programmes.
The programme will also focus on the evaluation and validation of biotech products and indigenous discovery, innovation and technology to products with focus on the products of national relevance or public benefit. BIPP is an advanced technology initiative by the DBT for supporting innovative and challenging R&D in industry.
Under the scheme, support will also be available for setting up of infrastructure and facility. In cases where such a facility leads to R&D capacity building or is required for scale up of an innovative product/process of national importance developed through company’s in-house R&D, facility proposed could be in the area of agriculture, healthcare, biosimilars, industrial processes, energy, bioinformatics, genomics and other relevant areas in biotechnology.
A single or consortia of Indian companies–small, medium or large– having DSIR recognized in-house R&D units, alone or in collaboration with a partner from another company/university/ institute/organization can be part of the programme. The interested biotech companies can apply for the proposal till March 31 this year.
Even as fresh reports appeared in the Western media about the rise of spurious drugs in India, the Government has categorically stated that there were no reports to substantiate the allegations coming out still about Indian industry.
“There are no reports to indicate that availability of spurious medicines is on the rise in the country,” according to Union Health Minister Ghulam Nabi Azad recently in the Parliament. He also said the Government had taken several steps to check the problem of spurious and sub-standard drugs.
Very recently, a section of the US media had once again raised the issue of spurious drugs in India, in the backdrop of the visit of Margaret A Hamburg, the commissioner of the United States Food and Drug Administration (FDA), to the country. Indian Industry supplies 40 per cent of over-the-counter and generic prescription drugs consumed in the United States. The report had also claimed that World Health Organization estimated that one in five drugs made in India are fakes. A 2010 survey of New Delhi pharmacies found that 12 per cent of sampled drugs were spurious.
“This had been cleared long back after the WHO formally informed Health Ministry that there was no such survey done by it in India. It is no more a debatable issue,” a senior official from the Health Ministry told Pharmabiz about the report.
During the meeting with the US FDA Commissioner last week, the Union Minister had also clearly countered the allegations saying that “cheap drugs did not mean that they were spurious”.
Detailing the steps taken to check the spurious drugs, the ministry sources said the States/UTs were requested to set up special Courts for trial of offences under the Drugs and Cosmetics Act for speedy disposal. So far 16 States have already set up designated special Courts for trial of cases related to spurious and sub-standard drugs.
Guidelines for taking action on samples of drugs declared spurious or not-of-standard quality in the light of enhanced penalties under the Drugs & Cosmetics (Health Ministry asserts that no reports of rise in spurious drugs in IndiaAmendment) Act, 2008 were forwarded to the State Drugs Controllers for uniform implementation. The inspectorate staff have been instructed to keep vigil and draw samples of drugs for test and analysis to monitor the quality of drugs moving in the country, sources said.
Global Ayurveda Festival 2014 is primarily sponsor by DHATHRI GROUP!
Speakers at Global Ayurveda Festival 2014.
Sponsors & Associates – Global Ayurveda Festival 2014.
Global Ayurveda Festival – Kerala (GAF) is a biennial get together of the Ayurveda fraternity in the State of Kerala, where Ayurveda has retained its traditional sanctity. The virgin form of Ayurveda in Kerala has been augmented with immense regional innovations and improvements to take the shape and form that we see today, popular as Kerala Ayurveda.The GAF has established itself as a vibrant platform with a mandate to galvanize the Ayurveda sector to aspire, plan and achieve greater heights, both nationally and internationally. It is not conceived merely as another conference or expo but a popular resurgence to venerate the glory and splendour of a living heritage that every Ayurveda exponent and fan will feel proud to embrace.
The second edition of this much anticipated Festival is being held at Kochi, the commercial hub of Kerala, from 20thto 24th February 2014.
The event will look to build on the strengths of the first edition of Global Ayurveda Festival to reach out to a much wider audience for an unprecedented
impact that brings about a visible positive change in the sector.
Highlights of Global Ayurveda Festival 2014
- The largest event in the heartland of authentic Ayurveda
- Five days International Expo with more than 350 stalls
- Visitations by more than 2,00,000 people
- Over 4,000 delegates for the International Seminar
- Ayurveda Specialty Clinics by eminent clinicians
- Awareness programmes on Ayurveda for students and public
- International Business Meet
- Scientific talks by outstanding thought leaders, researchers and international faculty
- Curtain raiser events and road shows
- Ayurveda and ethnic food carnivals
- Exhibition of rich medicinal plant diversity of India
- Ayurveda Book Fair
- The first ever Ayurveda Paramedics Conference
- Ayurveda Herbs Cultivators and Collectors Meet
Components of GAF
Global Exhibition on Ayurveda – Arogya Expo
International Seminar- Ayurveda in Public Health
- Ayurveda Solidarity Meets
Political leaders Meet
- Media Meet
International Business Meet
International Cooperation Meet
Ayurveda Education Expo
Medicinal Plants Expo
Pre Conference Workshops
Research methodology, Biostatistics and Scientific writing
Guided Tours to
Centres of Clinical Excellence in Ayurveda
Accredited herbal drug and cosmetic manufacturing units
Public Awareness Programmes
Documentary Film Festival